Table 2

Multivariable Cox proportional hazards regression models for overall survival limited to patients who underwent LND with at least 10 pelvic nodes and at least one para-aortic node removed, in the entire group and stratified by lymph node status

Variable	Level	Overall		pN0		pN1/2
Variable	Level	Multivariable hazard ratio (95% CI)*	P value	Multivariable hazard ratio (95% CI)*	P value	Multivariable hazard ratio (95% CI)*	P value
LN surgery	LND only	1.0 reference		1.0 reference		1.0 reference
	SLN-B only	0.94 (0.74 to 1.20)	0.637	0.97 (0.74 to 1.27)	0.807	0.96 (0.56 to 1.62)	0.864
	SLN-B/LND	0.99 (0.76 to 1.28)	0.918	1.22 (0.89 to 1.66)	0.217	0.75 (0.48 to 1.18)	0.219
Age	Per 10 years	1.59 (1.50 to 1.68)	<0.001	1.67 (1.56 to 1.80)	<0.001	1.42 (1.29 to 1.57)	<0.001
Race	White	1.0 reference		1.0 reference		1.0 reference
	Black	1.49 (1.33 to 1.68)	<0.001	1.62 (1.39 to 1.89)	<0.001	1.40 (1.16 to 1.68)	<0.001
	Other	0.98 (0.80 to 1.21)	0.879	1.07 (0.83 to 1.39)	0.604	0.86 (0.61 to 1.22)	0.400
	Unknown	0.97 (0.63 to 1.49)	0.873	0.80 (0.44 to 1.45)	0.455	1.40 (0.74 to 2.64)	0.306
Charlson-Deyo score	0	1.0 reference		1.0 reference		1.0 reference
	1	1.22 (1.11 to 1.35)	<0.001	1.34 (1.19 to 1.51)	<0.001	1.07 (0.91 to 1.25)	0.443
	≥2	1.56 (1.31 to 1.85)	<0.001	1.57 (1.27 to 1.95)	<0.001	1.54 (1.15 to 2.04)	0.003
Insurance status	Private Insurance	1.0 reference		1.0 reference		1.0 reference
	Not insured	1.35 (1.07 to 1.71)	0.010	1.61 (1.19 to 2.17)	0.002	1.08 (0.75 to 1.57)	0.643
	Medicaid	1.37 (1.13 to 1.66)	0.001	1.28 (0.98 to 1.68)	0.074	1.39 (1.05 to 1.83)	0.021
	Medicare	1.15 (1.03 to 1.28)	0.012	1.23 (1.07 to 1.41)	0.003	1.05 (0.88 to 1.26)	0.596
	Other government	1.12 (0.72 to 1.74)	0.625	0.97 (0.53 to 1.76)	0.907	1.51 (0.77 to 2.95)	0.233
	Unknown	0.98 (0.66 to 1.47)	0.938	0.88 (0.47 to 1.65)	0.690	0.99 (0.59 to 1.68)	0.976
Income	≥$63 333	1.0 reference		1.0 reference		1.0 reference
	$50 354–63 332	1.0 (0.89 to 1.13)	0.947	1.09 (0.94 to 1.26)	0.264	0.92 (0.75 to 1.12)	0.396
	$40 227–50 353	1.08 (0.95 to 1.23)	0.226	1.13 (0.96 to 1.32)	0.134	1.0 (0.81 to 1.23)	0.962
	<$40 227	1.06 (0.91 to 1.23)	0.490	1.18 (0.97 to 1.43)	0.100	0.93 (0.73 to 1.19)	0.575
	Unknown	0.56 (0.18 to 1.75)	0.318	0.78 (0.11 to 5.54)	0.801	0.58 (0.14 to 2.37)	0.447
Education (% no HSD)	≥17.6%	1.06 (0.91 to 1.25)	0.440	1.01 (0.82 to 1.24)	0.929	1.06 (0.82 to 1.37	0.646
	10.9%–17.5%	1.06 (0.93 to 1.22)	0.400	1.06 (0.89 to 1.26)	0.530	0.99 (0.79 to 1.24)	0.898
	6.3%–10.8%	1.17 (1.04 to 1.32)	0.008	1.23 (1.06 to 1.43)	0.006	1.05 (0.86 to 1.29)	0.620
	<6.3%	1.0 reference		1.0 reference		1.0 reference
	Unknown	2.71 (0.83 to 8.88)	0.099	2.54 (0.34 to 18.83)	0.362	1.62 (0.34 to 7.72	0.548
Facility type	Community	1.15 (0.93 to 1.43)	0.189	1.28 (0.97 to 1.69)	0.081	1.02 (0.73 to 1.43)	0.914
	Comprehensive community	1.05 (0.95 to 1.15)	0.346	1.10 (0.98 to 1.23)	0.112	0.99 (0.85 to 1.16)	0.926
	Academic	1.0 reference		1.0 reference		1.0 reference
	Integrated network	0.95 (0.84 to 1.07)	0.356	1.01 (0.87 to 1.17)	0.943	0.86 (0.71 to 1.05)	0.146
	Unknown	2.09 (1.29 to 3.39)	0.003	1.60 (0.77 to 3.30)	0.207	2.50 (1.29 to 4.85)	0.007
AJCC pathological N stage	pN0	1.0 reference		–		–
	pN1	1.72 (1.52 to 1.94)	<0.001	–		1.0 reference
	pN2	1.91 (1.69 to 2.17)	<0.001	–		1.14 (0.99 to 1.30)	0.069
AJCC pathological T stage	pT1	1.06 (0.61 to 1.84)	0.824	1.0 (0.54 to 1.88)	0.991	1.34 (0.42 to 4.25)	0.624
	pT1A	1.0 reference		1.0 reference		1.0 reference
	pT1B	1.62 (1.45 to 1.82)	<0.001	1.58 (1.39 to 1.80)	<0.001	1.53 (1.19 to 1.97)	<0.001
	pT2	2.29 (2.00 to 2.61)	<0.001	2.22 (1.87 to 2.63)	<0.001	2.18 (1.69 to 2.81)	<0.001
	pT3/3A/3B	2.94 (2.58 to 3.33)	<0.001	3.10 (2.61 to 3.70)	<0.001	2.71 (2.14 to 3.44)	<0.001
Grade	Well/moderately	1.0 reference
	Poorly/undifferentiated	2.0 (1.78 to 2.24)	<0.001	1.93 (1.68 to 2.22)	<0.001	2.13 (1.73 to 2.62)	<0.001
	Unknown	1.66 (1.47 to 1.87)	<0.001	1.58 (1.37 to 1.83)	<0.001	1.83 (1.47 to 2.29)	<0.001
Lymph vascular invasion	Not present	1.0 reference		1.0 reference		1.0 reference
	Present	1.53 (1.39 to 1.69)	<0.001	1.61 (1.43 to 1.80)	<0.001	1.37 (1.15 to 1.64)	<0.001
	Unknown	1.05 (0.88 to 1.26)	0.567	1.04 (0.84 to 1.29)	0.732	0.99 (0.71 to 1.38)	0.952
Histology	1	1.0 reference		1.0 reference		1.0 reference
Histology	2	1.62 (1.47 to 1.79)	<0.001	1.62 (1.43 to 1.84)	<0.001	1.59 (1.37 to 1.86)	<0.001
Adjuvant chemotherapy	No chemotherapy received	1.0 reference		1.0 reference		1.0 reference
Adjuvant chemotherapy	Chemotherapy received	0.87 (0.78 to 0.96)	0.006	0.89 (0.78 to 1.02)	0.082	0.79 (0.65 to 0.94)	0.010
Adjuvant hormone therapy	No hormone therapy received	1.0 reference		1.0 reference		1.0 reference
	Hormone therapy received	1.22 (0.74 to 2.0)	0.437	0.77 (0.36 to 1.61)	0.482	1.77 (0.90 to 3.46)	0.099
	Unknown	1.02 (0.78 to 1.33)	0.895	1.03 (0.73 to 1.44)	0.882	0.99 (0.65 to 1.51)	0.973
Adjuvant radiation therapy	No radiation	1.0 reference		1.0 reference		1.0 reference
	Brachytherapy	0.79 (0.71 to 0.88)	<0.001	0.84 (0.74 to 0.95)	0.004	0.67 (0.53 to 0.86)	0.002
	External beam	0.82 (0.74 to 0.91)	<0.001	0.84 (0.72 to 0.99)	0.033	0.78 (0.67 to 0.91)	0.001
	Other	0.78 (0.43 to 1.41)	0.412	0.45 (0.17 to 1.21)	0.114	1.22 (0.57 to 2.60)	0.609

*Hazard ratios estimate the risk of an event (death for any cause) in each group compared with that of the reference group. Hazard ratios lower than one represent a risk of events lower than the reference group, whereas hazard ratios higher than one represent a higher risk of events.
AJCC, American Joint Committee on Cancer; HSD, high-school diploma; LN, lymph node; LND, lymphadenectomy; SLN-B, sentinel lymph node biopsy.